Repligen Corporation (NASDAQ:RGEN) – First Analysis increased their FY2017 earnings per share estimates for shares of Repligen Corporation in a report issued on Wednesday. First Analysis analyst now forecasts that the biotechnology company will post earnings of $0.60 per share for the year, up from their previous forecast of $0.55. First Analysis has a “Equal Weight” rating and a $40.00 price target on the stock. First Analysis also issued estimates for Repligen Corporation’s Q4 2017 earnings at $0.16 EPS and FY2018 earnings at $0.72 EPS.

Repligen Corporation (NASDAQ:RGEN) last released its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported $0.20 earnings per share for the quarter, topping analysts’ consensus estimates of $0.15 by $0.05. The business had revenue of $32.40 million for the quarter, compared to analysts’ expectations of $31.72 million. Repligen Corporation had a return on equity of 9.90% and a net margin of 15.61%. The company’s revenue was up 11.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.16 EPS.

TRADEMARK VIOLATION WARNING: “FY2017 EPS Estimates for Repligen Corporation Increased by Analyst (RGEN)” was posted by Watch List News and is the property of of Watch List News. If you are viewing this article on another website, it was stolen and republished in violation of US & international copyright and trademark laws. The original version of this article can be read at https://www.watchlistnews.com/fy2017-eps-estimates-for-repligen-corporation-increased-by-analyst-rgen/1472044.html.

A number of other research firms have also commented on RGEN. BidaskClub upgraded shares of Repligen Corporation from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 24th. Janney Montgomery Scott raised their price objective on shares of Repligen Corporation from $42.00 to $47.00 in a research note on Friday, June 23rd. Jefferies Group LLC reiterated a “hold” rating and set a $40.00 price objective (up previously from $33.00) on shares of Repligen Corporation in a research note on Wednesday, June 28th. William Blair began coverage on shares of Repligen Corporation in a research note on Friday, July 21st. They set an “outperform” rating on the stock. Finally, Zacks Investment Research lowered shares of Repligen Corporation from a “buy” rating to a “hold” rating in a research note on Wednesday, July 5th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $41.20.

Repligen Corporation (RGEN) traded up 0.41% during midday trading on Friday, hitting $41.24. The company had a trading volume of 75,164 shares. Repligen Corporation has a 12-month low of $26.16 and a 12-month high of $46.81. The stock has a market cap of $1.54 billion, a price-to-earnings ratio of 80.70 and a beta of 1.30. The company’s 50 day moving average is $41.88 and its 200 day moving average is $36.55.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Norges Bank acquired a new position in Repligen Corporation during the fourth quarter valued at about $8,527,000. Teachers Advisors LLC boosted its position in Repligen Corporation by 11.4% in the fourth quarter. Teachers Advisors LLC now owns 56,695 shares of the biotechnology company’s stock valued at $1,747,000 after buying an additional 5,819 shares during the last quarter. Macquarie Group Ltd. boosted its position in Repligen Corporation by 481.1% in the fourth quarter. Macquarie Group Ltd. now owns 319,668 shares of the biotechnology company’s stock valued at $9,852,000 after buying an additional 264,659 shares during the last quarter. Bank of Montreal Can boosted its position in Repligen Corporation by 26.1% in the first quarter. Bank of Montreal Can now owns 37,036 shares of the biotechnology company’s stock valued at $1,304,000 after buying an additional 7,675 shares during the last quarter. Finally, Louisiana State Employees Retirement System boosted its position in Repligen Corporation by 1.5% in the first quarter. Louisiana State Employees Retirement System now owns 13,800 shares of the biotechnology company’s stock valued at $486,000 after buying an additional 200 shares during the last quarter. Hedge funds and other institutional investors own 99.02% of the company’s stock.

Repligen Corporation Company Profile

Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.

Earnings History and Estimates for Repligen Corporation (NASDAQ:RGEN)

Receive News & Ratings for Repligen Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.